cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Recruiting
Observational Study
Brain Cancer
Breast Cancer
Bladder Cancer
Cervical Cancer
Colorectal Cancer
Endometrial Cancer
Esophageal Cancer
Stomach Cancer
Head and Neck Cancer
Hepatobiliary Cancer
Leukemia
Lung Cancer
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Sarcoma
Thyroid Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 40 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 7,000 (estimated)
- Sponsor
- Adela, Inc · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, p…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Case Inclusion Criteria:
* Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagnosed \>5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancre…
Contacts